Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of ...

As Donald Trump prepares to assume the presidency on January 20, 2025, the healthcare industry faces a period of potential ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

In Upslope’s view, CRL is a cyclical compounder going through a…cyclical downturn. Why are we bullish CRL stock? Click here ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.